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Abstract 
Hypertension and proteinuria are important mediators of renal damage. Despite therapeutic 
interventions, the number of patients with end stage renal disease steadily increases. 
Hydrogen sulfide (H2S) is an endogenously produced gasotransmitter with vasodilatory, anti-
inflammatory and antioxidant properties. These beneficial characteristics make H2S an 
attractive candidate for pharmacological use in hypertensive renal disease. We investigated 
the protective properties of H2S in Angiotensin II (Ang II)-induced hypertensive renal disease 
in rats. Treatment with the H2S donors NaHS and sodium thiosulfate (STS) during three weeks 
of Ang II infusion reduced hypertension, proteinuria, oxidative stress and renal functional and 
structural deterioration. In an ex vivo isolated perfused kidney setup NaHS, but not STS, 
reduced intrarenal pressure. The effect of NaHS could partially be explained by its activation 
of the ATP-sensitive potassium channels. In conclusion, treatment with H2S attenuates Ang II-
associated functional and structural renal deterioration, suggesting that intervention in H2S 
production pathways has potential therapeutic benefit and might be a valuable addition to 
the already existing antihypertensive and renoprotective therapies. 
 




1 Introduction    
Chronic kidney disease (CKD) is a highly prevalent disorder associated with extensive 
morbidity and mortality worldwide. Hypertension and proteinuria are major contributors to 
the progression of CKD. Both are important actors in enhancing structural and functional renal 
deterioration through changes in intrarenal hemodynamics and inflammation, thereby 
promoting the release of chemokines and reactive oxygen species (ROS).(1,4) This results in 
stimulation of extracellular matrix synthesis and enhancement of cellular apoptosis. Increased 
activity of the renin-angiotensin-aldosterone system (RAAS) resulting in augmented 
Angiotensin II (Ang II) signaling is often the underlying cause of hypertension and proteinuria. 
Functional RAAS modulation has afforded great progress in renoprotection by reducing 
blood pressure, proteinuria and the rate of renal function loss. Although RAAS blockade 
stands out as the most effective renoprotective treatment, in many cases renal disease 
ultimately progresses to end-stage renal failure with the deplorable need for dialysis or 
transplantation.(5,6) This prompts for additional modes of intervention by either optimization 
of RAAS blockade based therapies or targeting other pathophysiological pathways involved 
in the development of CKD.  
 Hydrogen Sulfide (H2S) is acknowledged as the third gasotransmitter in addition to nitric 
oxide (NO) and carbon monoxide (CO), and modulates many physiological functions.(7) It is 
endogenously produced from the amino acid L-cysteine by cystathionine γ-lyase (CSE) and 
cystathionine β-synthase (CBS)(8,9) and from D-cysteine by 3-mercaptopyruvate 
sulfurtransferase (3-MST).(10) In the vasculature H2S functions as an endothelial cell-derived 
relaxing factor via direct activation of ATP-sensitive potassium (KATP) channels.(11) 
Accordingly, CSE-deficient mice and CBS heterozygous mice develop hypertension.(12,13) 
CSE can act as an endogenous modulator of oxidative stress, as CSE-deficient mice have 
increased renal damage after ischemia-reperfusion.(14)  Exogenous treatment with the soluble 
sulfide salt NaHS attenuated the hypertensive effects of NO synthase (NOS) inhibition(15) and 
has preventive and therapeutic effects on renovascular hypertension by inhibiting plasma 
renin activity.(16) In addition, H2S stimulates cellular proliferation(17) and angiogenesis,(18) 
and reduces inflammation.(19,20) Endogenous H2S functions as a signaling molecule by 
regulating protein activity through S-sulfhydration which is a form of posttranslational 
modification.(21,22) Furthermore, H2S can play a detoxifying role during oxidative stress by 
direct scavenging of ROS or increasing the formation of the antioxidant glutathione.(23,24) 
Progression of renal disease in a CKD model is associated with depletion of H2S and its 
producing enzymes.(25) Recently, urinary sulfur metabolites were found to associate with a 
favorable cardiovascular risk profile and even improved survival in renal transplant 
recipients.(26) Given the cytoprotective features of H2S, its deficiency may contribute to 
progression of CKD and its systemic complications.  
 H2S can be delivered in vivo via gaseous administration or through the use of soluble 
sulfide salts like NaHS and Na2S. In addition, several slow-release H2S donors have been 
developed. Another possibility is the use of thiosulfate (TS), an endogenous actor in the 
enzymatic pathways of H2S modulation in mammalian cells. Increasing evidence grounds the 
idea that a dynamic conversion exists between the two substances.(27-29) In humans, the 
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short term therapeutic use of sodium TS (STS) has been proven safe(30) for the treatment of 
calciphylaxis.(31) 
 The vasodilating and cytoprotective features of H2S make it an attractive therapeutic 
candidate for reducing the damaging effects of hypertension and proteinuria. In the 
experimental setting, Ang II infusion causes hypertension, proteinuria and renal damage.(32) 
We used this model to investigate the renoprotective properties of sulfide containing 
compounds.  
2 Materials and methods 
2.1 Animals 
Male Sprague Dawley rats (240-280 gram, Harlan, Zeist, the Netherlands) were housed under 
standard conditions with a 12 hour light-dark cycle at the animal research facility with ad 
libitum access to food and water. Experimental procedures were in agreement with 
institutional and legislator regulations and approved by the local ethics committee for animal 
experiments. 
2.2 Ang II infusion and NaHS or STS treatment 
Osmotic minipumps (model 2004, Alzet, Cupertino, CA, USA) were placed subcutaneously 
under general anesthesia (2% Isoflurane/O2) for continuous administration of Ang II (435 
ng/kg/min, n = 7/group; Bachem, Weil am Rhein, Germany) or vehicle (0.9% NaCl, n = 6). 
Post-operatively, all rats received a subcutaneous injection of 50 μg/kg buprenorphin 
(Schering-Plough, Houten, the Netherlands) for analgesic purposes and were allowed to 
recover from surgery at 37°C in a ventilated incubator. At placement of the pumps Ang II-
infused rats were randomized to either 0.9% NaCl, NaHS (5.6 mg/kg/day; Sigma, Zwijndrecht, 
the Netherlands) or STS (1 g/kg/day; Sigma, Zwijndrecht, the Netherlands) treatment. 0.9% 
NaCl-infused rats received treatment with 0.9% NaCl. During the three weeks of infusion rats 
received intraperitoneal (ip) injections with one of the compounds twice a day. At baseline, 
blood was collected via orbital puncture. On a weekly basis body weight was measured and 
rats were placed in metabolic cages for collection of 24-hour urine. Chlorhexidin was added 
to the urine as an antiseptic agent to prevent bacterial growth. After three weeks blood 
pressure was measured under general anesthesia (2% Isoflurane/O2) via an intra-aortic probe 
(Cardiocap/5, GE Healthcare, Little Chalfont, Buckinghamshire, UK). Subsequently, rats were 
sacrificed and blood was collected in heparin and EDTA containing tubes and centrifuged for 
10 minutes at 1000 rcf. Plasma was collected and stored at -80°C. Kidneys were perfused with 
0.9% NaCl. Coronal slices were fixed in 4% paraformaldehyde and paraffin embedded for 
immunohistochemical analysis or immediately snap frozen in liquid nitrogen and stored at -
80°C for molecular analysis. 
2.3 Plasma and urine biochemical analysis 
Plasma and urine levels of creatinine, urea and electrolytes were determined by standard 
assays from Roche on the Roche Modular (Roche Diagnostics GmbH, Mannheim, Germany) 
 




according to routine procedures in our clinical chemical laboratory. Urinary protein levels were 
determined with the pyrogallol red molybdate method.(33) Urinary TS was determined by a 
specific HPLC method as described previously.(30,34) In short, 25 μL of urine was derivatized 
with 5 μL of 46 mM monobromobimane, 25 μL of acetonitrile, and 25 μL of 160 mM HEPES/16 
mM EDTA pH 8 buffer (Invitrogen, Carlsbad, CA, USA) for 30 minutes in the dark. 
Derivatization of thiol groups was stopped by 50 μL of 65 mM methanosulfonic acid (Fluka, 
Buchs, Switzerland) and proteins were removed by recentrifugation.  
2.4 Qualitative Real-time Polymerase Chain Reaction 
Rat renal tissue containing cortex and medulla was homogenized in lysis buffer and total RNA 
was extracted using the TRIZOL method (Invitrogen, Carlsbad, USA). RNA concentrations 
were measured by a nanodrop UV-detector (Nanodrop Technologies, Wilminton, DE). cDNA 
was synthesized using Superscript II with random hexamer primers (Invitrogen, Carlsbad, 
USA). Gene expression (Applied Biosystems, Foster City, CA, USA) was determined by 
qualitative realtime-PCR (qRT-PCR) based on the Taqman methodology. HPRT was used as a 
housekeeping gene with the following primers (Integrated DNA Technologies) and probe 
(Eurogentec): Forward: 5'-GCC CTT GAC TAT AAT GAG CAC TTC A-3’, Reverse: 5'-TCT TTT 
AGG CTT TGT ACT TGG CTT TT-3’ and Probe: 6-FAM 5'-ATT TGA ATC ATG TTT GTG TCA 
TCA GCG AAA GTG-3' TAMRA. The other primers were obtained from Applied Biosystems 
as Assays-on-Demand (AOD) gene expression products. The AOD ID’s used were: Coll3a1 
(Collagen 3) Rn01437683_m1, Acta2 (αSMA) Rn01759928_g1, Havcr1 (KIM-1) 
Rn00597703_m1, CTH (CSE) Rn00567128_m1, CBS Rn00560948_m1, Mpst (3-MST) 
Rn00593744_m1, Renin Rn00561847_m1, TGF-β1 Rn00572010_m1 and Cybb (NOX2) 
Rn00576710_m1. The qRT-PCR reaction mixture contained 20 ng cDNA template and 5μl 
PCR-mastermix. Nuclease free water was added to a total volume of 10 μl. All assays were 
performed in triplicate. The thermal profile was 15 minutes at 95°C, followed by 40 cycles of 
15 seconds at 95°C and 1 minute at 60°C. The average Ct values for target genes were 
subtracted from the average housekeeping gene Ct values to yield the delta Ct. Results were 
expressed as 2-ΔCt. 
2.5 Immunohistochemistry  
For immunostaining, deparaffinized sections were subjected to heat-induced antigen retrieval 
by overnight incubation with 0.1 M Tris/HCl buffer (pH 9.0) at 80°C (ED1, αSMA, KIM-1, 
desmin) or by incubation with EDTA buffer (pH 8.0) heated by a microwave (Collagen 3). 
Endogenous peroxidase was blocked with 0.075% H2O2 in phosphate buffered saline (PBS, 
pH 7.4) for 30 minutes. Primary antibodies for macrophages (mouse anti-CD68 ED1, 
MCA341R AbD, 1:750, Serotec Ltd, Oxford, UK), αSMA (mouse anti-SMA, clone 1A4 A2547, 
1:10.000, Sigma, Zwijndrecht, the Netherlands), Collagen 3 (goat anti-type 3 Collagen, 1330-
01, 1:75, Southern Biotech, Birmingham, Alabama, USA), Desmin (mouse anti-desmin NCL-
DES-DER11, 1:500, Novocastra, Rijswijk, the Netherlands) or KIM-1 (rabbit anti-KIM-1 peptide 
9, 1:400, gift V. Baily) were incubated for 60 minutes at room temperature. Binding was 
detected using sequential incubation with peroxidase-labeled secondary and tertiary 
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antibodies (Dakopatts, Glostrup, Denmark) for 30 minutes. All antibodies were diluted with 
PBS supplemented with 1% BSA. At the secondary and tertiary antibody dilutions 1% normal 
rat serum was added. Peroxidase activity was developed using 3,3’-diaminobenzidine 
tetrachloride for 10 minutes containing 0.03% H2O2. Counterstaining was performed using 
Mayer’s hematoxylin. Appropriate isotype and PBS controls were consistently negative. 
2.6 Analysis of histopathological changes 
Kidney sections were scanned using an Aperio Scanscope GS (Aperio Technologies, Vista, 
CA, USA). The extent of fibrotic changes (α-SMA, Collagen 3), glomerular damage (desmin) 
and proximal tubular ischemic damage (KIM-1) were determined using the Aperio positive 
pixel analysis v9.1 algorithm. For α-SMA, Collagen 3 and KIM-1 the ratio between the relative 
cortical staining intensity and the total cortical surface area was used. For desmin the ratio 
between glomerular staining intensity and total cortical glomerular area was calculated. 
Interstitial macrophages were counted manually by random selection of thirty renal cortical 
high powered fields. Histopathological analysis was performed in a blinded fashion. 
2.7 Urinary malondialdehyde measurements 
Malondialdehyde (MDA), a major breakdown product of lipid peroxides, is generated after 
oxidative stress. MDA is a thiobarbituric acid-reactive substance and can be ﬂuorescently 
measured after binding to thiobarbituric acid. Twenty μL urine was incubated with 90 μL of 
3% SDS and 10 μL of 0.5 M butylated hydroxytoluene followed by addition of 400 μL 0.1 N 
HCl, 50 μL 10% phosphotungstic acid and 200 μL 0.7% 2-Thiobarbituric acid. The reaction 
mixture was incubated for 30 minutes at 95°C. After adding 800 μL of 1-butanol, the samples 
were centrifuged at 960 g for 10 minutes. Two hundred μL of the 1-butanol phase was 
ﬂuorescently measured using 530 nm excitation and 590 nm emission wavelengths. 
2.8 Isolated perfused kidney setup 
To investigate the effect of NaHS and STS on intrarenal pressure we used an ex vivo isolated 
perfused kidney (IPK) setup. After induction of anaesthesia with 2% Isoflurane/O2, both 
kidneys and renal vessels from five healthy rats were isolated via a midline incision and 
subsequently a cannula was placed in the renal artery. Depending on the renal vascular 
anatomy either the right or left kidney was used. After placement in the IPK setup, the kidney 
was continuously perfused via the renal artery with warmed (37°C) and oxygenated (95% O2 
and 5% CO2 gas mixture) Krebs-Ringer Bicarbonate (KRB) solution complemented with 
albumin and creatinine at a pH of 7.5 ± 0.05 and a PO2 ≈ 60 kPa, by using a roller pump 
(Ismatec mv-ca/04; Ismatec, Glattbrugg, Switzerland) delivering a constant flow of 8 mL/min 
throughout the experiment. The composition of the perfusion solution was as follows: 118.6 
mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 
6.1 mM glucose, 7.1 mM creatinine and 50 g/L albumin. After connecting the kidney, the flow 
was gradually increased to 8 mL/min. Vascular responses were monitored by an 
electromechanical pressure transducer (Cobe; Arvada, CO) connected to a computer 
interface (LabView, National Instruments, Austin, TX). After an equilibration period, when 
 




renal vascular pressure had stabilized, 1-2 μM of phenylephrine (PE) (Sigma, Zwijndrecht, the 
Netherlands) was added to the perfusate to obtain a stable pre-contraction pressure of 200-
250 mmHg. When the PE-induced vasoconstriction had reached a plateau, kidneys were 
subjected to subsequent doses of NaHS (1 μM, 10 μM, 100 μM, 1 mM and 5 mM (n=5)) or 
STS (1 μM (n=5), 10 μM, 100 μM (n=2), 1 mM, 5 mM (n=5)) for 1 minute. To investigate the 
role of KATP channels in NaHS-induced vasodilation, kidneys (n=5) were continuously perfused 
with 1 mM of Glibenclamide (Sigma, Zwijndrecht, the Netherlands) and subjected to 
subsequent doses of NaHS. After every dose we conducted a washout period of 4 minutes or 
continued when the intrarenal pressure had returned to baseline. 
2.9 Statistical analysis 
Data were analyzed and graphed using GraphPad Prism 5.0 software (GraphPad, San Diego, 
CA, USA). Statistical analyses were performed using t-tests, Mann-Whitney U tests, two-way 
ANOVA, one-way ANOVA or Kruskal-Wallis tests where appropriate. Bonferroni, Dunnett’s or 
Dunn’s postcorrection was applied where multiple comparisons were made. Normality was 
tested using the Kolmogorov-Smirnov test. Statistical significance was accepted at p<0.05. 
All data are expressed as the mean ± standard error of the mean (SEM) unless indicated 
otherwise. 
3 Results 
3.1 Rat characteristics – body weight and electrolytes  
At baseline, there were no significant differences in body weight between the groups (Tab. 
1). After 3 weeks, vehicle treated Ang II-infused rats had a significantly lower body weight 
compared to NaCl-infused controls (p<0.001). Treatment with NaHS partially prevented Ang 
II-induced weight loss (NaHS: p<0.05) (Tab. 1). Plasma sodium was significantly lower in 
vehicle treated rats compared to controls (p<0.001). No differences between groups were 
observed in plasma potassium and calcium levels (Tab. 1). In STS treated rats, urinary sodium 
excretion was significantly higher compared to vehicle treated rats (p<0.01). Urinary excretion 
of calcium was increased in Ang II-infused rats treated with vehicle compared to controls 
(p<0.05). Urinary excretion of potassium did not differ between groups (Tab. 1). 
3.2 NaHS and STS treatment attenuated Ang II-induced hypertension 
Ang II infusion increased both systolic (211 ± 9 mmHg vs. 143 ± 2 mmHg, p<0.001) and 
diastolic (127 ± 10 mmHg vs. 84 ± 2 mmHg, p<0.01) blood pressure compared to controls. 
Simultaneous treatment with either NaHS or STS decreased systolic blood pressure (SBP) by 
22% (164 ± 3 mmHg, p<0.001) and 18% (173 ± 7 mmHg, p<0.001), and diastolic blood 
pressure (DBP) by 26% (93 ± 8 mmHg, p<0.05) and 30% (89 ± 7 mmHg, p<0.01), respectively 
(Fig. 1A and B). Infusion with Ang II reduced mRNA levels of renin in all groups compared to 
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Table 1: Weight and biochemical parameters at baseline and the end of the study 
Minipump treatment NaCl Ang II 
Daily injection NaCl NaCl NaHS STS 
Body weight (gram)  baseline 266 ± 7 261 ± 4 269 ± 4 262 ± 5 
week 3 304 ± 20 211 ± 5 ### 266 ± 16 * 257 ± 16 
Plasma sodium (mmol/L) 145 ± 0.9 139 ± 0.9 ### 142 ± 1.0 142 ± 0.8 
Plasma potassium (mmol/L) 4.1 ± 0.2 3.8 ± 0.2 3.7 ± 0.4 3.7 ± 0.3 
Plasma calcium (mmol/L) 2.1 ± 0.1 2.2 ± 0.1 2.2 ± 0.1 2.3 ± 0.1 
Urinary sodium (mmol/24 h) 2.2 ± 0.7 2.6 ± 0.3 1.7 ± 0.4 4.9 ± 0.5 ** 
Urinary potassium (mmol/24 h) 1.8 ± 0.3 1.9 ± 0.1 1.7 ± 0.2 2.0 ± 0.3 
Urinary calcium (mmol/24 h) 0.01 ± 0.01 0.08 ± 0.01 # 0.05 ± 0.02 0.10 ± 0.02 
Data are expressed as mean ± SEM. #p<0.05, ###p<0.001 vs. control; *p<0.05, **p<0.01 vs. Ang II + NaCl. 
 
Figure 1: Treatment with NaHS and STS attenuated Ang II-induced hypertension and Ang II 
infusion caused downregulation of renin mRNA expression 
Infusion with Ang II increased (A) systolic 
blood pressure by 48% and (B) diastolic 
blood pressure by 51%. Treatment with 
NaHS and STS significantly attenuated the 
Ang II-induced hypertension. (C) Infusion 
with Ang II caused downregulation of renin 
mRNA levels in all groups. (#p<0.05, 
##p<0.01, ###p<0.001 vs. control, *p<0.05, 
**p<0.01, *** p<0.001 vs. Ang II + NaCl) 
 




3.3 Improved renal function and reduced proteinuria in NaHS and STS treated rats 
Renal function - reflected by creatinine clearance and plasma urea - and proteinuria were 
similar in all groups at baseline (data not shown). After three weeks of Ang II infusion, vehicle 
treated rats had an impaired renal function as reflected by a 67% reduction in creatinine 
clearance (1.4 ± 0.1 mL/min vs. 4.2 ± 0.2, p<0.001) and a 2.9-fold increase in plasma urea 
(19.0 ± 1.0 mmol/L vs. 6.5 ± 0.2 mmol/L, p<0.001) compared to control rats (Fig. 2A and B). 
Furthermore, proteinuria was significantly increased from week 2 onwards (346 ± 35 mg/24 h 
vs. 28 ± 11 mg/24 h, p<0.001) (Fig. 2C). After three weeks of treatment with NaHS or STS, 
renal function loss was partially prevented as evidenced by a higher creatinine clearance 
(NaHS: 2.5 ± 0.3 mL/min, p<0.05; STS: 2.9 ± 0.5 mL/min, p<0.001) and lower plasma urea 
levels (NaHS: 14 ± 2 mmol/L, p<0.01; STS: 14 ± 2 mmol/L, p<0.01) compared to vehicle 
treated rats (Fig. 2A and B). From week 2 onwards, the 24-hour urinary protein excretion was 
significantly moderated by NaHS and STS treatment (NaHS: 179 ± 75 mg/24 h, p<0.001; STS: 
197 ± 58 mg/24 h, p<0.01) (Fig. 2C).  




Three weeks of Ang II 
infusion decreased renal 
function as evidenced by 
a 67% decrease in (A) 
creatinine clearance and 





from week 2 onwards. 
Treatment with NaHS and 
STS reduced renal 
function loss by 
preserving the creatinine 
clearance and plasma 
urea levels. In addition, 
the development of 
proteinuria was 
diminished in NaHS and 
STS treated rats from 
week 2 onwards. 
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3.4 STS increased the excretion of urinary TS  
From week 1 onwards, the excretion of urinary TS (p<0.001) was significantly increased in Ang 
II-infused rats treated with STS. No differences were observed in the other groups (Fig. 3). 
Figure 3: Elevated urinary TS excretion in STS treated animals 
In rats treated with STS, the excretion of urinary TS was increased from week 1 onwards. In all other 
groups no differences in urinary TS levels were observed. (***p<0.001 vs. Ang II + NaCl) 
3.5 Effect of NaHS and STS treatment on tubular and glomerular damage 
After 3 weeks, kidney injury molecule-1 (KIM-1) mRNA and protein expression were increased 
in Ang II-infused rats treated with vehicle compared to controls (p<0.001). Both NaHS and 
STS treated rats showed less tubular damage as evidenced by a 2-fold reduction in proximal 
tubular damage at mRNA and protein level compared to vehicle treated animals (p<0.05) 
(Fig. 4A, B and C). Also, the glomerular damage marker desmin was increased after three 
weeks of Ang II infusion (p<0.001). Treatment with NaHS, but not STS, decreased the 









Figure 4: Effect of NaHS and STS treatment on tubular damage  
 
(A) KIM-1 mRNA and (B) KIM-1 protein levels were increased by Ang II infusion. Rats treated with NaHS 
and STS had less tubular damage as evidenced by reduced KIM-1 protein and mRNA levels. (C) 
Representative photomicrographs of KIM-1 stained renal sections. (###p<0.001 vs. control, *p<0.05 
vs. Ang II + NaCl) 
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Figure 5: Effect of NaHS and STS treatment on glomerular damage   
 
 (A) Desmin protein levels were increased in glomeruli of Ang II-infused animals treated with vehicle. 
Treatment with NaHS reduced glomerular desmin levels by 40%. Treatment with STS only showed a 
trend towards decreased desmin levels. (B) Representative photomicrographs of desmin stained renal 
sections. (###p<0.001 vs. control, **p<0.01 vs. Ang II + NaCl) 
3.6 Influx of macrophages is reduced by treatment with STS 
Ang II infusion increased the number of ED1 positive cells in the renal interstitium more than 
2-fold compared to NaCl infused controls (204 ± 46 vs. 86 ± 12, p<0.05). STS and NaHS 
decreased the number of interstitial macrophages to near control levels (STS: 73 ± 21, p<0.01; 
NaHS 114 ± 18, p=0.06) (Fig. 6A and B).      
Figure 6: Interstitial inflammation is reduced by treatment with STS 
  
(A) The influx of macrophages was increased 2-fold in Ang II-infused rats treated with vehicle. 
Treatment with STS, but not NaHS, reduced the number of interstitial macrophages 3-fold. 
(B) Representative photomicrographs of ED-1 stained renal sections. (#p<0.05 vs. control, 
**p<0.01 vs. Ang II + NaCl) 
 




3.7 Treatment with NaHS and STS reduced oxidative stress 
Expression of NOX2 mRNA was increased 1.6-fold after Ang II infusion (p<0.05) (Fig. 7A). 
Furthermore, the urinary excretion of malondialdehyde (MDA) was increased more than 2-
fold in Ang II rats treated with vehicle (p<0.001) (Fig. 7B). Simultaneous treatment with either 
NaHS or STS decreased NOX2 mRNA expression by 38% (p<0.01) and 39% (p<0.01), and 
urinary MDA levels by 35% (p<0.05) and 30% (p<0.05), respectively (Fig. 7A and B).  
Figure 7: Treatment with NaHS and STS reduced oxidative stress    
After three weeks of Ang II infusion, (A) NOX2 mRNA and (B) urinary MDA levels were increased 1.6-
fold and 2-fold, respectively. Treatment with NaHS and STS reduced NOX2 mRNA expression by 38% 
and 39% and urinary MDA levels by 35% and 30%, respectively. (#p<0.05, ###p<0.001 vs. control, 
*p<0.05, **p<0.01 vs. Ang II + NaCl) 
3.8 Protective effects of NaHS and STS treatment against renal interstitial changes  
TGF-β, a growth factor with proliferative and fibrotic effects on myofibroblasts, is significantly 
upregulated during Ang II infusion (p<0.05). In rats treated with NaHS and STS, levels of TGF-
β mRNA return to near control values (p<0.01) (Fig. 8A). Ang II infusion significantly increased 
mRNA (p<0.05) and protein (p<0.001) expression of the pre-fibrotic marker α-smooth muscle 
actin (αSMA), indicating ongoing interstitial myofibroblast transformation. STS, but not NaHS, 
decreased the mRNA and protein expression of αSMA by 50% (p<0.05) (Fig. 8B, C and D). 
The pre-fibrotic effects of Ang II were accompanied by increased fibrotic damage, as 
evidenced by a significantly higher expression of Collagen 3 mRNA and protein (p<0.05). 
Treatment with NaHS and STS reduced the development of fibrosis, resulting in a reduction 
of Collagen 3 mRNA (p<0.05) and protein (NaHS: p<0.05; STS: p<0.001) to near control levels 
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Figure 8: Effect of NaHS and STS on renal fibrosis  
(A) In rats infused with Ang II and treated with vehicle, renal TGF-β mRNA levels were upregulated. 
Treatment with NaHS and STS prevented the upregulation of TGF-β. Ang II infusion caused 
upregulation of (B) αSMA mRNA and (C) αSMA protein expression. STS, but not NaHS, decreased the 
levels of αSMA protein and mRNA. (D) Representative photomicrographs of αSMA stained renal 
sections. (E) Collagen 3 mRNA and (F) Collagen 3 protein levels were increased in Ang II-infused rats 
treated with vehicle. In NaHS and STS treated rats the formation of Collagen 3 was decreased. (G) 
Representative photomicrographs of Collagen 3 stained renal sections. (#p<0.05, ###p<0.001 vs. 
control, *p<0.05, **p<0.01, ***p<0.001 vs. Ang II + NaCl) 
 




3.9 Restoration of CSE, CBS and 3-MST mRNA expression with NaHS and STS treatment 
Renal mRNA expression of CSE, CBS and 3-MST was significantly decreased after 3 weeks of 
Ang II infusion (p<0.01). Expression levels were partially restored in Ang II-infused rats that 
received NaHS and STS (p<0.05) (Fig. 9A, B and C). 
Figure 9: Treatment with NaHS and STS restored the expression of CSE, CBS and 3-MST mRNA 
3.10 Vasodilatory effects of NaHS in the isolated perfused kidney setup 
Administration of 1 and 5 mM NaHS lowered intrarenal pressure by 44% (p<0.001) and 39% 
(p<0.05) compared to baseline pressure during phenylephrine (PE) constriction. Lower 
concentrations of NaHS had no effect on intrarenal pressure. To investigate the role of KATP 
channels in NaHS-induced vasodilation kidneys were perfused with Glibenclamide, which 
diminished the vasodilatory potency of 1 mM NaHS (p<0.05). STS showed no effect on 
intrarenal pressure (Fig. 10, next page). 
After three weeks of Ang II infusion, renal 
mRNA levels of (A) CSE, (B) CBS and (C) 3-
MST are decreased. Treatment with NaHS 
and STS partially prevented this down 
regulation. (##p<0.01, ###p<0.001 vs. 
control, *p<0.05 vs. Ang II + NaCl) 
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Figure 10: NaHS lowered intrarenal pressure partly via activation of KATP-channels 
In an IPK setup a stable pre-constriction pressure of 200-250 mmHg was induced by perfusion with 1-
2 μM PE. Administration of 1 and 5 mM NaHS lowered intrarenal pressure. Simultaneous perfusion with 
1 mM Glibenclamide reduced the vasodilatory properties of 1 mM NaHS significantly. Concentrations 
of NaHS below 1 mM and all concentrations of STS had no effect on intrarenal pressure. (#p<0.05, 
###p<0.001 vs. baseline pressure, *p<0.05 vs. NaHS)  
4 Discussion 
Exogenous treatment with sulfide donors reduces hypertension, proteinuria, renal damage 
and renal function loss associated with Ang II infusion. Furthermore, we are the first to show 
that STS, a clinically applicable compound, has promising renoprotective properties. These 
data suggest that intervention in sulfur pathways has protective potential in hypertension and 
hypertensive renal disease.  
 The effects of exogenous H2S on blood pressure reduction are in line with previous 
literature showing its preventive and therapeutic properties in experimental hypertension. 
Endogenous H2S shortage is suggested to be involved in the pathogenesis of 
hypertension.(11-13,15,35) One of the underlying mechanisms in blood pressure reduction 
by H2S is its direct effect on vascular smooth muscle cells by sulfhydration and subsequent 
activation of KATP-channels.(11) The effects of H2S on proteinuria are described less clearly and 
not in a rectilinear fashion.(36,37) The antiproteinuric effects of H2S in our model, as 
structurally evidenced by preservation of podocytes, can be partially explained by the 
reduction of systemic and intrarenal pressures. Mechanistic evidence for this comes from our 
ex vivo isolated perfused kidney (IPK) experiments in which we observed a reduction in 
intrarenal pressure by NaHS. Blockage of the KATP-channels partly decreased the vasodilatory 
potency of NaHS, suggesting that other mechanisms are involved as well. One of these might 
be crosstalk between H2S and NO, since the vasorelaxant effects of H2S are partly NO-
dependent. Inhibition of NO using L-NG-nitroargininemethyl ester (L-NAME) decreased the 
potency of H2S in aortic rings.(38) The in vivo effects of STS were unmistakable, but could not 
be related to direct changes in intrarenal pressure in our IPK setup. Since it is known that TS 
 




can be converted to H2S in vivo, we suggest that the IPK setup lacks the proper physiological 
conditions necessary for this conversion.  
 H2S directly affects the RAAS, as shown by its capacity to inhibit renin activity and ACE 
activity.(16) Since we infused Ang II, the contribution of this mechanism is probably low or 
undetectable because of the existing negative feedback loop between Ang II and renin. 
Indeed we found low mRNA levels of renin in all the Ang II treated groups. Furthermore, H2S 
can decrease Ang II-induced activation of mitogen-activated protein kinases and the binding 
affinity of the Angiotensin-1 (AT-1) receptor in a dose-dependent manner.(39)  
 Although it is plausible that blood pressure regulation is the primary mechanism of action 
of H2S in our model, it is known that renal injury in Ang II-induced hypertension can be 
independent of an elevated blood pressure. This suggests additional protective modes of 
action of H2S. Since we did not include a group receiving conventional antihypertensive drugs 
during Ang II infusion, we cannot determine whether the protective effects of H2S are solely 
mediated by blood pressure reduction.   
 Inflammation is one of the major consequences of renal exposure to hypertension and 
proteinuria.(4) STS completely prevented Ang II-induced influx of interstitial macrophages, 
whereas NaHS only showed a trend. H2S is widely known for its anti-inflammatory properties 
and its role in modulation of leukocyte influx.(19,40-44) Since proteinuria causes tubular 
damage and subsequent production of chemokines and attraction of macrophages,(45) the 
anti-inflammatory effects of H2S can also be explained by a reduction in proteinuria and a 
subsequent decline in tubular damage, as evidenced by decreased KIM-1 mRNA and protein 
levels.    
 Treatment with H2S influences renal fibrotic pathways as evidenced by a reduction in 
collagen 3 mRNA and protein, and a downregulation of TGFβ mRNA in both treatment 
groups. The attenuation of fibrosis by H2S treatment is in concordance with literature showing 
decreased fibrosis in various organs following H2S exposure.(42,46-48) STS outperformed 
NaHS with regard to decreased αSMA levels, which might be related to the lower level of 
interstitial macrophages in the former. Other studies showed an inhibiting effect of H2S on 
αSMA formation.(49,50)     
 Another functional property of H2S relates to the inhibition of ROS production. Ang II 
induces oxidative stress by activating NADPH oxidases via the AT-1 receptor.(51) We found 
diminished ROS production in H2S treated animals as evidenced by lower urinary MDA levels. 
This might be related to the prevented upregulation of NOX2 in both H2S treated groups, 
which is in line with literature showing the effect of H2S on NADPH oxidases.(52) H2S can also 
directly scavenge ROS, increase the intracellular glutathione levels, and reduce the amount 
of ROS produced through modulation of mitochondrial ROS production.(14,23,24) Loss of 
endogenous H2S-production causes increased susceptibility to renal ischemia.(14) Production 
of ROS plays an important role in the development of hypertension(53) and treatment with 
antioxidants reduces blood pressure in experimental models for hypertension.(54,55)   
 Interestingly, we observed a decline in CSE, CBS and 3-MST mRNA levels in the Ang II-
infused animals treated with vehicle. Considering the vasorelaxing properties of H2S we 
expected a compensatory increase in these enzymes. However, levels of H2S and/or its 
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producing enzymes were also decreased in other models of disease in which one might 
expect compensatory upregulation.(14,25,56-58) There is a concordance between 
progression of renal disease and the decline in H2S producing capacity of renal tissue,(25) 
suggesting that depleted levels of endogenous H2S production enhance renal damage. We 
have not measured H2S since the reliability of the available techniques is controversial. 
Treatment with NaHS and STS restored the expression of CSE, CBS and 3-MST which is 
probably related to a reduction in proteinuria and subsequent salvage of tubular cells, which 
are major producers of these enzymes. These expression data suggest that there is a shortage 
in renal endogenous H2S production in hypertensive renal disease, which implies that 
intervention in the H2S producing pathway might be valuable to increase renal levels of 
sulfide.  
 The observation that STS as a H2S donor(27-29) has similar protective effects as NaHS, 
provides us with exciting possibilities for the translation into clinical use. While short term 
treatment with STS is well tolerated, the long term side effects should be further explored. 
One of the drawbacks for long term administration to renal patients is the currently available 
route of delivery. To date, STS is only given intravenously to patients with calciphylaxis 
because oral forms of the compound with a validated intestinal uptake have not been 
developed. It is unknown whether the observed effects of STS are solely mediated by 
conversion to H2S or by unknown direct effects of STS itself. Animals treated with STS had 
significantly increased sulfate levels, indicating that conversion to H2S and sulfite took place 
before forming sulfate.28 Effects of STS on blood pressure in humans have not been described 
extensively; however there are indications that STS exhibits vasodilating effects and 
antioxidant properties,(59-61) probably via the conversion to H2S.(27-29)  
 Taken together, our data reveal novel protective modalities of H2S treatment in 
experimental renal disease. Therefore, intervention in H2S related pathways may have 
therapeutic potential in hypertension and hypertensive renal damage and deserves further 
exploration for clinical application.  
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